Ii-Key-H1 swine influenza vaccine

The **Ii-Key-H1 swine influenza vaccine** is an experimental vaccine candidate developed by Generex Biotechnology in response to the 2009 H1N1 swine flu outbreak. It leverages the **Ii-Key technology**, a proprietary peptide-based platform that enhances MHC class II presentation of vaccine antigens to boost CD4+ T-cell responses and immunogenicity. The vaccine incorporates an H1 antigen derived or adapted from an existing H5 vaccine component, aiming to elicit protective immunity against swine influenza A H1N1 virus. Revitalized amid the pandemic, it represents an early-stage effort to improve peptide vaccine efficacy for rapid pandemic response, though no detailed clinical trial data or current development status is publicly documented.

Other names

Ii-Key-H1 peptide vaccineIi-Key-H-1 peptide vaccineIi-Key-H 1 peptide vaccineIi-Key peptide hybrid construct